Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sana Biotechnology, Inc.NASDAQ: SANA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $24.02M fell 38.7% year over year, behind the -4.6% change in trailing-twelve-month research & development. Sequentially, it fell 51.0% from the prior quarter. Over 3 fiscal years it compounded at -13.1% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.7% toward the trailing-twelve-month pace of -4.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 131.98M USD
- Year-over-year change
- -36.8%
- 4-year CAGR
- -19.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 131.98M | -36.8% |
| FY2024 | 2024-12-31 | 208.68M | -5.1% |
| FY2023 | 2023-12-31 | 219.84M | +9.4% |
| FY2022 | 2022-12-31 | 201M | -34.4% |
| FY2021 | 2021-12-31 | 306.5M | — |
Research & Development vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 research & development of $146.28M is the 6th highest of the 11 companies compared; the peer median is $158.58M.
- Its year-over-year change of -4.6% is the 4th highest of 11, against a peer median of -16.2%.
- Over three fiscal years its annual growth of -13.1% compares with a peer median of -1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Sep 2026 | $378.58M | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $146.28M | -4.6% | -13.1% | — | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $10.18M | -92.4% | -48.4% | 44.0% | |
| Peer median (excluding SANA) | $158.58M | -16.2% | -1.5% | 261.9% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 12.75M |
| Gross Profit | 0 | 0 | 0 | 0 | (12.75M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 306.5M | 201M | 219.84M | 208.68M | 131.98M |
| Selling, General & Admin | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M |
| Operating Expenses | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| EBITDA | (344.86M) | (253.85M) | (258.7M) | (249.37M) | (231.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (356.91M) | (272.56M) | (293.14M) | (272.72M) | (190.96M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 676K | 3.76M | 9.94M | 10.47M | 3.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 981K | 3.09M | 9.89M | 5.96M | (53.21M) |
| Income Before Tax | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| EPS (Diluted) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| Weighted Avg Shares | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
| Weighted Avg Shares (Diluted) | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.